Hikma buys rights to FDA-approved cancer treatment trametinib, a generic version of Novartis' (NVS) Mekinist, with 180 days ...

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S.

J.P. Morgan analyst Richard Vosser reiterated a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strategic reviews and potential interest, fluctuations in stock ...

Swiss pharmaceutical firm Novartis AG plans to invest $23 billion in the US over the next five years to ensure its key drugs ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Novartis plans to invest $23 billion in US sites as Trump renews drug tariff threats Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in ...

North Carolina economic development officials terminated several incentives grants this week, including some tied to companies with operations in the Triangle.